AlloVir (ALVR) IPO Opens 18% Higher

Today's IPO for AlloVir (NASDAQ: ALVR) opened for trading at $20 after pricing 16,250,000 shares of common stock at a public offering price of $17 per share.

AlloVir has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of AlloVir’s common stock at the initial public offering price, less underwriting discounts and commissions.

Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler & Co. are acting as joint book-running managers for the offering.

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

You May Also Be Interested In

• Vogenx prices IPO at $13 per share, raising $81.3M
• ACV names Tim Fox as chief financial officer, effective August 2026
• Barrick Mining (B) PT Lowered to $54 at BofA Securities